Anti-PD-L1 Monoclonal Antibody(Avelumab),Starter_specification/price/image

Product Detail
Company Profile

Product Specification

Host	Human
Antigen	PD-L1
Synonyms	Programmed cell death 1 ligand 1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1
Accession	Q9NZQ7
Clone Number	S-SC012
Antibody Type	Recombinant mAb
Isotype	IgG1,λ
Application	Blocking of PD-1/PD-L1 signaling Functional assays
Purification	Protein A
Concentration	2 mg/ml
Endotoxin	<1EU/mg
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS pH7.4, containing no preservative
Stability & Storage	12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution

application	dilution	species
ELISA	1.221-5000 ng/ml

Background

Avelumab is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab targets the protein programmed death-ligand 1 (PD-L1).

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.